Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 3;8(8):e2968. doi: 10.1038/cddis.2017.352

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

The miR-125a-3p/FUT5-FUT6 axis mediates the activity of the PI3K/Akt signalling pathway. (a) In SW480 cells transfected with anti-miR-125a-3p, FUT5 or FUT6, PI3K p110α, Thr308, Ser473 and NF-kB were greatly increased, and (b) an opposite result was found in SW620 cells transfected with miR-125a-3p-mimics, FUT5 shRNA or FUT6 shRNA. (c) In addition, western blotting showed that PI3K110α, Akt Thr308, Akt Ser473, Akt and NF-kB were decreased by LY294002 treatment or Akt siRNA in SW620 cells. The results of the (d) colony-formation assay, (e) transwell invasion assay, and (f) endothelial tube formation assay, showed that proliferation, invasion and angiogenesis abilities of SW620 cells were reduced by LY294002 treatment or Akt siRNA. Tumour growth was significantly decreased in nude mice given by LY294002 treatment or transfected with Akt siRNA based on (g) immunostaining, (h) tumour growth curves and (i) tumour weight (*P<0.05)